Back to today’s briefing

Story perspectives

UK Pre-Surgery Pembrolizumab Trial Shows Zero Recurrences.

6/1/2026

22 3 Full Breakdown

Summary

Story summary

UK trial of pembrolizumab given before surgery reported zero cancer recurrences after three years.
Thirty-two patients with stage 2 or 3 MMR-deficient bowel cancer received the treatment and remain disease-free.
Chief investigator Dr Kai-Keen Shiu described the results as extremely encouraging.
Patient Elise Sargent, 45, said the therapy does not help all genetic mutations and called for FIT screening to start at age 40.

1 of 1

Story summary

UK trial of pembrolizumab given before surgery reported zero cancer recurrences after three years.
Thirty-two patients with stage 2 or 3 MMR-deficient bowel cancer received the treatment and remain disease-free.
Chief investigator Dr Kai-Keen Shiu described the results as extremely encouraging.
Patient Elise Sargent, 45, said the therapy does not help all genetic mutations and called for FIT screening to start at age 40.